Literature DB >> 27723670

Transcatheter aortic valve implantation through extra-anatomic iliac graft in a patient with unsuitable iliofemoral and subclavian anatomy.

Ali Doğan1, Emrah Özdemir2, Denyan Mansuroğlu3, Kenan Sever3, Yelda Saltan2, Behzat Özdemir2, Ulviye Yılmaz2, Nuri Kurtoğlu2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27723670      PMCID: PMC5324946          DOI: 10.14744/AnatolJCardiol.2016.7097

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


× No keyword cloud information.

Introduction

Transcathater aortic valve implantation (TAVI) has emerged as a promising alternative for patients with severe, symptomatic aortic stenosis who are not candidates for surgery due to high comorbidity and operation mortality (1, 2). Transfemoral approach (TF) is the generally accepted route for TAVI. However, small vessel diameter and peripheral arterial disease hinder this access (3). Presently described is experience with TAVI through extra-anatomic iliac graft as an alternative approach.

Case Report

A 73-year-old female was admitted to the clinic with dyspnea and hospitalized with diagnosis of acute pulmonary edema. Patient had history of hypertension and hyperlipidemia, and had undergone coronary artery bypass graft and carotid endarterectomy 6 years prior. After treatment for acute heart failure, echocardiographic examination revealed severe aortic stenosis with peak gradient of 109 mm Hg, mean gradient of 60 mm Hg, and aortic valve area of 0.6 cm2 with left ventriculer ejection fraction of 57% and pulmonary hypertension (systolic pulmonary artery pressure: 63 mm Hg). Patient had calculated logistic EuroSCORE of 37.9%, Society of Throracic Surgeons score of 16.8% and New York Heart Association (NYHA) class III functional capacity. Multislice computed tomography (MSCT) indicated that bilateral common femoral arteries were severely calcified with diameter diminished to 4.0 and 3.8 mm (right and left femoral arteries, respectively) (Fig. 1). It also revealed that right and left subclavian artery had 5.0 mm and 5.2 mm diameter, respectively. Right subclavian artery was severely calcified.
Figure 1

Multislice computed tomography (3-dimensional reconstruction) showing stenosis of femoral arteries, making them unsuitable for TAVI. Common femoral arteries were severely calcified with diameter 4.0 and 3.8 mm (right and left femoral arteries, respectively)

Multislice computed tomography (3-dimensional reconstruction) showing stenosis of femoral arteries, making them unsuitable for TAVI. Common femoral arteries were severely calcified with diameter 4.0 and 3.8 mm (right and left femoral arteries, respectively) MSCT was used for valve size calculation. Aortic annulus diameter, area, and perimeter measurements were 21x25 mm, 428 mm2, and 74 mm, respectively. Before TAVI procedure, due to unsuitable iliofemoral anatomy for conventional TF approach, extra-anatomic bypass grafting to left iliac artery was performed by vascular surgeons under general anesthesia. Common iliac artery was reached with left retroperitoneal incision, and 8 mm expanded polytetrafluoroethylene graft (Carboflo,® Impra Inc., Tempe, AZ, USA) was sutured end to side. Graft was removed from incision and clamped (Fig. 2). Afterward, TAVI procedure was initiated. A pigtail catheter was placed in aortic root through right femoral artery, a temporary pacemaker lead was placed in right ventricle through right femoral vein and procedure was performed through left aortoiliac graft. Amplatz 0.035 inch, 260 cm super stiff guidewire (Boston Scientific Corporation; Natick, Mass., USA), was passed through pigtail catheter to reach left ventricle apex. After dilatation with 25x40 mm balloon, 26 mm Edwards SAPIEN bioprosthetic (Edwards Lifesciences LLC; Irvine, Calif., USA) valve was deployed optimally. No complication or aortic regurgitation was observed after procedure. Postoperatively, graft was ligated and sutured 2 cm above anastomotic line. Echocardiography showed that peak and mean transvalvular gradients decreased to 18 and 7 mm Hg, respectively, and valve area increased to 1.9 cm2. Patient’s functional capacity was improved to NYHA 1 during first month of follow-up.
Figure 2

Polytetrafluoroethylene graft was removed for insertion of TAVI equipment

Polytetrafluoroethylene graft was removed for insertion of TAVI equipment

Discussion

In a study investigating use of Edwards SAPIEN 3, TF route could be used only in 64% of patients (4). Transapical, subclavian, carotid, and direct aortic access routes have been developed as alternatives to TF approach (5). Recently, a study based on UK TAVI registry revealed transapical and direct aortic approach had higher mortality than TF route. Subclavian access mortality was found to be similar to TF and evaluated as safest nonfemoral access route for TAVI (6). In present case, TAVI was performed through left iliac graft. Heart team decided not to use transapical or direct aortic approach because of higher mortality rates. Carotid approach was not selected due to patient’s history of carotid endarterectomy. For subclavian approach, artery diameter should be at least 6 mm for 18 French sheath in absence of calcification (5). However, patient’s subclavian arteries were not appropriate for this access due to reduced vessel size and severely calcified nature of right subclavian artery. To our knowledge, this is the first report of extra-anatomic iliac graft for TAVI. There is 1 study in the literature that used TF approach through left aorto-iliac graft to deploy Edwards SAPIEN valve; however, that case involved a patient who had existing bilateral aortoiliac graft (7). Present patient was treated successfully and no complication was observed during follow-up. Caution should be taken with regard to graft size for insertion of TAVI equipment and anastomosis-related complications such as hematoma and infection.

Conclusion

In patients with anatomy unsuitable to femoral or subclavian access, extra-anatomic iliac graft can be used safely and it could be accepted as an alternative, novel route for TAVI.
  7 in total

1.  Comparative survival after transapical, direct aortic, and subclavian transcatheter aortic valve implantation (data from the UK TAVI registry).

Authors:  Georg M Fröhlich; Paul D Baxter; Christopher J Malkin; D Julian A Scott; Neil E Moat; David Hildick-Smith; David Cunningham; Philip A MacCarthy; Uday Trivedi; Mark A de Belder; Peter F Ludman; Daniel J Blackman
Journal:  Am J Cardiol       Date:  2015-09-03       Impact factor: 2.778

Review 2.  Management of vascular access in transcatheter aortic valve replacement: part 1: basic anatomy, imaging, sheaths, wires, and access routes.

Authors:  Stefan Toggweiler; Jonathon Leipsic; Ronald K Binder; Melanie Freeman; Marco Barbanti; Robin H Heijmen; David A Wood; John G Webb
Journal:  JACC Cardiovasc Interv       Date:  2013-07       Impact factor: 11.195

3.  Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry.

Authors:  Neil E Moat; Peter Ludman; Mark A de Belder; Ben Bridgewater; Andrew D Cunningham; Christopher P Young; Martyn Thomas; Jan Kovac; Tom Spyt; Philip A MacCarthy; Olaf Wendler; David Hildick-Smith; Simon W Davies; Uday Trivedi; Daniel J Blackman; Richard D Levy; Stephen J D Brecker; Andreas Baumbach; Tim Daniel; Huon Gray; Michael J Mullen
Journal:  J Am Coll Cardiol       Date:  2011-10-20       Impact factor: 24.094

Review 4.  Transcatheter aortic valve implantation: new developments and upcoming clinical trials.

Authors:  Christos V Bourantas; Vasim Farooq; Yoshinobu Onuma; Nicolo Piazza; Nicolas M Van Mieghem; Patrick W Serruys
Journal:  EuroIntervention       Date:  2012-09       Impact factor: 6.534

5.  Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description.

Authors:  Alain Cribier; Helene Eltchaninoff; Assaf Bash; Nicolas Borenstein; Christophe Tron; Fabrice Bauer; Genevieve Derumeaux; Frederic Anselme; François Laborde; Martin B Leon
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

6.  Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve.

Authors:  John Webb; Gino Gerosa; Thierry Lefèvre; Jonathon Leipsic; Mark Spence; Martyn Thomas; Matthias Thielmann; Hendrik Treede; Olaf Wendler; Thomas Walther
Journal:  J Am Coll Cardiol       Date:  2014-11-24       Impact factor: 24.094

7.  Transcatheter aortic valve implantation through a left aortoiliac graft.

Authors:  Mehmet Gul; Ozgur Akgul; Mehmet Erturk; Abdurrahman Eksik; Aydin Yildirim
Journal:  Tex Heart Inst J       Date:  2012
  7 in total
  2 in total

1.  Author`s Reply.

Authors:  Ali Doğan
Journal:  Anatol J Cardiol       Date:  2017-02       Impact factor: 1.596

2.  Transcathater aortic valve implantation in transapical access.

Authors:  Orhan Gökalp; Mehmet Senel Bademci; Yüksel Beşir; Hasan İner; Ali Gürbüz
Journal:  Anatol J Cardiol       Date:  2017-02       Impact factor: 1.596

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.